Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

162 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prevalence of specific neutralizing antibodies against Sendai virus in populations from different geographic areas: implications for AIDS vaccine development using Sendai virus vectors.
Hara H, Hara H, Hironaka T, Inoue M, Iida A, Shu T, Hasegawa M, Nagai Y, Falsey AR, Kamali A, Anzala O, Sanders EJ, Karita E, Mwananyanda L, Vasan S, Lombardo A, Parks CL, Sayeed E, Krebs M, Cormier E, Ackland J, Price MA, Excler JL. Hara H, et al. Among authors: excler jl. Hum Vaccin. 2011 Jun;7(6):639-45. doi: 10.4161/hv.7.6.15408. Epub 2011 Jun 1. Hum Vaccin. 2011. PMID: 21508675
Factors, enablers and challenges for COVID-19 vaccine development.
Excler JL, Saville M, Privor-Dumm L, Gilbert S, Hotez PJ, Thompson D, Abdool-Karim S, Kim JH. Excler JL, et al. BMJ Glob Health. 2023 Jun;8(6):e011879. doi: 10.1136/bmjgh-2023-011879. BMJ Glob Health. 2023. PMID: 37277195 Free PMC article. Review.
A Phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C-modified vaccinia Ankara virus vaccine candidate in Indian volunteers.
Ramanathan VD, Kumar M, Mahalingam J, Sathyamoorthy P, Narayanan PR, Solomon S, Panicali D, Chakrabarty S, Cox J, Sayeed E, Ackland J, Verlinde C, Vooijs D, Loughran K, Barin B, Lombardo A, Gilmour J, Stevens G, Smith MS, Tarragona-Fiol T, Hayes P, Kochhar S, Excler JL, Fast P. Ramanathan VD, et al. Among authors: excler jl. AIDS Res Hum Retroviruses. 2009 Nov;25(11):1107-16. doi: 10.1089/aid.2009.0096. AIDS Res Hum Retroviruses. 2009. PMID: 19943789 Clinical Trial.
AIDS vaccines and preexposure prophylaxis: is synergy possible?
Excler JL, Rida W, Priddy F, Gilmour J, McDermott AB, Kamali A, Anzala O, Mutua G, Sanders EJ, Koff W, Berkley S, Fast P. Excler JL, et al. AIDS Res Hum Retroviruses. 2011 Jun;27(6):669-80. doi: 10.1089/AID.2010.0206. Epub 2010 Dec 16. AIDS Res Hum Retroviruses. 2011. PMID: 21043994 Free PMC article. Review.
Background morbidity in HIV vaccine trial participants from various geographic regions as assessed by unsolicited adverse events.
Schmidt C, Smith C, Barin B, Bakhtyari A, Bart PA, Bekker LG, Chomba E, Clumeck N, Ho D, Hoosen A, Jaoko W, Kaleebu P, Karita E, Keefer MC, van Lunzen J, McMichael A, Mehendale S, Peters B, Ramanathan VD, Robinson A, Rockstroh J, Vardas E, Vets E, Weber J, Graham BS, Than S, Excler JL, Kochhar S, Ho M, Heald A, Fast PE. Schmidt C, et al. Among authors: excler jl. Hum Vaccin Immunother. 2012 May;8(5):630-8. doi: 10.4161/hv.19454. Epub 2012 May 1. Hum Vaccin Immunother. 2012. PMID: 22634443 Free article. Clinical Trial.
A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults.
Keefer MC, Gilmour J, Hayes P, Gill D, Kopycinski J, Cheeseman H, Cashin-Cox M, Naarding M, Clark L, Fernandez N, Bunce CA, Hay CM, Welsh S, Komaroff W, Hachaambwa L, Tarragona-Fiol T, Sayeed E, Zachariah D, Ackland J, Loughran K, Barin B, Cormier E, Cox JH, Fast P, Excler JL. Keefer MC, et al. Among authors: excler jl. PLoS One. 2012;7(8):e41936. doi: 10.1371/journal.pone.0041936. Epub 2012 Aug 3. PLoS One. 2012. PMID: 22870265 Free PMC article. Clinical Trial.
Safety and immunogenicity of DNA and MVA HIV-1 subtype C vaccine prime-boost regimens: a phase I randomised Trial in HIV-uninfected Indian volunteers.
Mehendale S, Thakar M, Sahay S, Kumar M, Shete A, Sathyamurthi P, Verma A, Kurle S, Shrotri A, Gilmour J, Goyal R, Dally L, Sayeed E, Zachariah D, Ackland J, Kochhar S, Cox JH, Excler JL, Kumaraswami V, Paranjape R, Ramanathan VD. Mehendale S, et al. Among authors: excler jl. PLoS One. 2013;8(2):e55831. doi: 10.1371/journal.pone.0055831. Epub 2013 Feb 13. PLoS One. 2013. PMID: 23418465 Free PMC article. Clinical Trial.
First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens.
Nyombayire J, Anzala O, Gazzard B, Karita E, Bergin P, Hayes P, Kopycinski J, Omosa-Manyonyi G, Jackson A, Bizimana J, Farah B, Sayeed E, Parks CL, Inoue M, Hironaka T, Hara H, Shu T, Matano T, Dally L, Barin B, Park H, Gilmour J, Lombardo A, Excler JL, Fast P, Laufer DS, Cox JH; S001 Study Team. Nyombayire J, et al. Among authors: excler jl. J Infect Dis. 2017 Jan 1;215(1):95-104. doi: 10.1093/infdis/jiw500. Epub 2016 Oct 17. J Infect Dis. 2017. PMID: 28077588 Free PMC article. Clinical Trial.
HIV-1 vaccines: challenges and new perspectives.
Excler JL, Robb ML, Kim JH. Excler JL, et al. Hum Vaccin Immunother. 2014;10(6):1734-46. doi: 10.4161/hv.28462. Epub 2014 Mar 17. Hum Vaccin Immunother. 2014. PMID: 24637946 Free PMC article. Review.
162 results